Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06897813
PHASE1
A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants
Sponsor: Zhejiang Wenda Pharma Technology LTD.
View on ClinicalTrials.gov
Summary
This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-910 in in Healthy Participants Detailed
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
68
Start Date
2025-06-30
Completion Date
2025-12-31
Last Updated
2025-04-02
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
WD-910 tablet
Administered P.O.
DRUG
WD-910 Tablets Placebo
Administered P.O.
Locations (1)
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia